Prof Evangelos Terpos discusses his study at EHA 2024, which evaluated a new method for adjusting belantamab mafodotin doses in transplant-ineligible patients with newly diagnosed multiple myeloma.

These patients were treated with an extended belantamab mafodotin dosing schedule in combination with lenalidomide and dexamethasone.

The study's results showed that a vision-related anamnestic tool was both safe and effective in guiding belantamab mafodotin dosing.

There was a high rate of agreement between the vision-related anamnestic tool and the ophthalmologist's 'assessment, particularly in cases of severe ocular adverse events (≥Gr3).